Latest Breaking News On - Ember 3 - Page 1 : vimarsana.com

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.

Aditya bardiaGregory vidalKomal jhaveriHr her2 breast cancerCdk4 6 inhibitorsSecond line therapiesEndocrine therapyEndocrine resistanceAkt inhibitorsCapitello 291Maintain trialEmber 3Oral serdsViktoria 1